6533b861fe1ef96bd12c5826
RESEARCH PRODUCT
Adherence to dietary treatment and clinical factors associated with anti-transglutaminase antibodies in celiac disease during the follow-up
Manuel LozanoManuel Alonso-garridoJuanjo PeiróMarta MiróLara Manyessubject
0301 basic medicinemedicine.medical_specialtyAbdominal painScience (General)PopulationDiseaseSerology03 medical and health sciencesQ1-3900302 clinical medicineAtrophyWeight lossInternal medicinemedicineTGA-IgA antibodiesCeliac diseaseeducationH1-99education.field_of_studyMultidisciplinarybiologybusiness.industryHLA-DQ2medicine.diseaseDietSocial sciences (General)030104 developmental biologyDietary non-complianceAnti-transglutaminase antibodiesbiology.proteinmedicine.symptombusiness030217 neurology & neurosurgeryResearch Articledescription
Introduction In clinical practice, celiac disease (CD) is monitored through anti-transglutaminase (TGA-IgA) antibody levels. The normalization of serum levels in successive periodic measurements indicates good response and adherence to dietary treatment. Objectives To evaluate the factors associated with the evolution of TGA-IgA antibodies and their association with dietary non-compliance and diseases related to CD. Methods This prospective observational study was carried out in 254 participants, who were recruited from patients from a hospital in southern Spain. Information about sex, age, serological test results, HLA DQ2/DQ8 haplotypes, mucosal atrophy, gastrointestinal and extra-intestinal symptoms, as well as diagnosis of diseases related to CD, was collected. Results Clinical manifestations, such as diarrhoea, abdominal pain and weight loss, showed differences according to sex and age. Children under 18 years of age presented a degree of total or severe atrophy of the intestinal villi. TGA-IgA antibodies concentrations were directly associated with the number of digestive disorders manifested by the patient and the record of dietary non-compliance and inversely related to the number of extra-digestive disorders. Conclusions Adolescents between 12 and 18 years old were the least monitored as well as the group with more extra-intestinal symptoms reported. Therefore, it is necessary to develop strategies in clinical practice aimed at this population group and continuous monitoring should be implemented to improve life quality and reduce complications that may arise in the long term.
year | journal | country | edition | language |
---|---|---|---|---|
2021-04-01 | Heliyon |